Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 1:51 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 7,824 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Acute Disease Clear all

Conditions: Pregnancy Complications, Obesity, Pre-Eclampsia, Gestational Diabetes
Interventions: Resistance exercise, Aerobic Exercise, Rest; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Epilepsy, Neurologic Disorder
Interventions: Cenobamate; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 70 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Otitis Media in Children, Chronic Otitis Media With Effusion, Recurrent Acute Otitis Media
Interventions: Tympanostomy tube; Device
Lead sponsor: David Chi, MD; Other
Eligibility: 6 Months to 14 Years
Enrollment: 386 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania • Sewickley, Pennsylvania

Conditions: Traumatic Brain Injury
Interventions: First Steps Educational Curriculum; Behavioral
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2008
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphocytic Leukemia, Myelodysplastic Syndromes
Interventions: Fludarabine + Total Marrow Irradiation; Combination Product
Lead sponsor: Naoyuki G. Saito, M.D., Ph.D.; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Alcoholism, Genetics
Interventions: Ethanol; Drug
Lead sponsor: National Institute on Alcohol Abuse and Alcoholism (NIAAA); NIH
Eligibility: 21 Years to 30 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Acute Myocardial Infarction, Acute Coronary Syndrome
Interventions: Cardiac troponin testing; Diagnostic Test
Lead sponsor: Fred Apple; Other
Eligibility: 18 Years and older
Enrollment: 2,286 participants
Timeline: 2017 – 2026
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Healthy (For Part A), Chronic Myeloid Leukemia (for Part B and C)
Interventions: Vodobatinib (K0706) capsules; Drug
Lead sponsor: Sun Pharma Advanced Research Company Limited; Industry
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 8
States / cities: Downey, California • Los Angeles, California • Jacksonville, Florida + 5 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: HEPAirX air filter, control air filter; Device
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Acute Respiratory Distress Syndrome (ARDS)
Interventions: ALT-100 mAb, ALT-100 (Placebo); Drug
Lead sponsor: Aqualung Therapeutics Corp.; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Stroke
Interventions: Screener, Standard of care; Other
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 80 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Obsessive-Compulsive Disorder
Interventions: dextro-amphetamine, Sham Comparison; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Stanford, California

Conditions: Long COVID
Interventions: Ketamine only; Drug
Lead sponsor: University of Texas at Austin; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia, Pediatric, Acute Myeloid Leukemia, Refractory
Interventions: CART123 cells; cyclophosphamide; fludarabine; Biological
Lead sponsor: University of Pennsylvania; Other
Eligibility: 1 Year to 29 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Leukemia
Interventions: tipifarnib; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 120 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2001
U.S. locations: 3
States / cities: Iowa City, Iowa • Baltimore, Maryland • Rochester, New York

Conditions: Covid19
Interventions: T89 capsule; Drug
Lead sponsor: Tasly Pharmaceuticals, Inc.; Industry
Eligibility: Not listed
U.S. locations: 1
States / cities: Tacoma, Washington

Conditions: Coronary Heart Disease
Interventions: dalcetrapib, placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 45 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 6
States / cities: Pensacola, Florida • Saginaw, Michigan • Saint Cloud, Minnesota + 2 more

Conditions: Depression, Depressive Disorder
Interventions: Aerobic Exercise, Paired Associative Stimulation; Behavioral · Device
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 50 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Leukemia, Myeloid, Acute
Interventions: CC-486, Venetoclax; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 8
States / cities: Stanford, California • Denver, Colorado • Boston, Massachusetts + 4 more

Conditions: Covid19
Interventions: Nasal Spray; Drug
Lead sponsor: Larkin Community Hospital; Other
Eligibility: 18 Years to 90 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Miami, Florida

Conditions: Coronary Disease
Interventions: rNAPc2; Drug
Lead sponsor: ARCA Biopharma, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Recurrent Adult Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
Interventions: choline magnesium trisalicylate, idarubicin, cytarabine, laboratory biomarker analysis; Drug · Other
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Myelodysplastic Syndrome, Leukemia
Interventions: FTS; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Drug Use, Alcohol Use, Congestive Heart Failure, Pneumonia, Acute Myocardial Infarction, Diabetes Mellitus, Chronic Obstructive Pulmonary Disease, End-Stage Renal Disease
Interventions: Specialized Community Disease Management, Treatment As Usual; Behavioral
Lead sponsor: Treatment Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Search by objective public record fields.

Acute Exercise Effects in Obese Pregnancy

Cenobamate in the Intensive Care Unit

Posterior vs. Anterior Tympanostomy Tube Placement

Acute Cognitive and Neurobehavioral Intervention: Efficacy Evaluation

A Dose Escalation Study of Intensity Modulated Total Marrow Irradiation (IMRT-TMI) Followed by Fludarabine as a Myeloablative Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed and Refractory Hematologic Malignancies

Genetics of the Acute Response to Alcohol in Social Drinkers

COmparisoN of High-sensitivity Cardiac TRoponin I and T ASsays Trial

Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies

Residential Cleaning of Indoor Air to Protect COPD Patients

Study of Safety and Efficacy of ALT-100mAb in Participants With Moderate/Severe ARDS

Reduce Inefficiencies in Management of Spasticity

Dextro-Amphetamine Versus Caffeine in Treatment-resistant OCD

Evaluating the Neuromodulatory Effect of Ketamine in Long COVID-19

CD123 Redirected T Cells for AML in Pediatric Subjects

R115777 in Treating Patients With Refractory or Recurrent Acute Leukemia or Chronic Myelogenous Leukemia

Expanded Access to T89 for Treatment Use in Intermediate-size Patients Population With COVID-19

A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE)

Acute Aerobic Exercise and Neuroplasticity in Depression

A Study to Assess Safety and Tolerability of CC-486 (ONUREG®, Oral Azacitidine) in Combination Therapy in Participants With Acute Myeloid Leukemia (AML)

Evaluation of the Efficacy of Xylitol Nasal Spray Against SARS-CoV-2

Anticoagulation With rNAPc2 to Eliminate MACE/TIMI 32

Choline Magnesium Trisalicylate and Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia

FTS Study in Patients With Advanced Hematologic Malignancies

Specialized Community Disease Management to Reduce Substance Use and Hospital Readmissions